FLAG-GO (CD33 ADC) lifts 5-year OS to 80% in frontline CBF-AML, blunting baseline mutation prognostic impact

Fludarabine/cytarabine/G-CSF (FLAG) is an intensive cytarabine-based induction/consolidation platform, and gemtuzumab ozogamicin (GO) is a CD33-directed antibody–drug conjugate; both were evaluated in a frontline Phase 2 CBF-AML study (NCT00801489). In 219 patients (median age 52; range 19–80), 51% received FLAG-GO and 49% FLAG-idarubicin; baseline co-mutations were common (49% kinase-pathway non–MAPK, 44% MAPK, 11% DNMT3A/ASXL1/TET2, 7% transcription-factor), yet on multivariable analysis these mutation classes did not significantly impact optimal PCR response (OPR; qPCR <0.1% end-induction and <0.01% during/after consolidation) or survival, while FLAG-GO favored both. Outcomes were strong: 5-year RFS/OS 67%/74% overall, and 77%/80% with FLAG-GO—numerically above many published benchmarks for “7+3 → HiDAC” in CBF-AML (often ~58–65% 5-year OS), aligning with prior evidence that adding GO to intensive chemo particularly benefits favorable-risk/CBF subsets (though GO benefits can be regimen- and dosing-schedule-dependent).